Abstract
Objective Diuretics reduce congestion in patients with heart failure with preserved ejection fraction (HFpEF). However, comparison of clinical effects across diuretic classes or combinations of diuretics in patients with HFpEF are not well described. Therefore, we sought to conduct a scoping review to map trial data of diuretic efficacy and safety in patients with HFpEF. Review methods and results We searched multiple bibliometric databases for published literature and ClinicalTrials.gov, and hand searched unpublished studies comparing different classes of diuretics to usual care or placebo in patients with HFpEF. We included randomised controlled trials or quasi-experimental studies. Two authors independently screened and extracted key data using a structured form. We identified 13 published studies on diuretics in HFpEF, with 1 evaluating thiazide use, 7 on mineralocorticoid receptor antagonists (MRAs) and 5 on sodium-glucose co-transporter 2 inhibitors (SGLT2i). There remain 17 ongoing trials evaluating loop diuretics (n=1), MRAs (n=5), SGLT2i (n=10) and a polydiuretic (n=1), including 2 well-powered trials of SGLT2i that will be completed in 2021. Conclusions The limited number of published trials evaluating different classes of diuretics in patients with HFpEF have been generally small and short term. Ongoing and emerging trials of single or combination diuretics with greater power will be useful to better define their safety and efficacy. Scoping review registration doi:10.18131/g3-dejv-tm77.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 593-605 |
| Number of pages | 13 |
| Journal | Heart |
| Volume | 108 |
| Issue number | 8 |
| DOIs | |
| State | Published - Apr 1 2022 |
Funding
Competing interests In the past 3 years, MH received funding from the World Heart Federation to serve as its senior programme advisor for the Emerging Leaders programme, which is supported by Boehringer Ingelheim and Novartis with previous support from BUPA and AstraZeneca. MH also receives support from the American Heart Association, Verily, AstraZeneca and American Medical Association for work unrelated to this research. The George Institute for Global Health’s wholly owned enterprise, George Health Enterprises, has received investment funds to develop fixed-dose combination products containing aspirin, statin and blood pressure lowering drugs. AA, MH, SJS and SK plan to submit patents for heart failure polypills, including for heart failure with preserved ejection fraction. SJS has received research grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, and R01 HL149423), the American Heart Association (#16SFRN28780016), Actelion, AstraZeneca, Corvia, Novartis and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapeutics, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Eisai, GSK, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Shifamed, Tenax and United Therapeutics. SK has received research grants from the American Heart Association (#19TPA34890060) and the National Institutes of Health (P30AG059988; P30DK092939).
Keywords
- diastolic
- drug interactions
- heart failure
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine